2 weeks Ago By Defense World Staff
Alliancebernstein L.P. raised its holdings in BioLife Solutions, Inc.
( NASDAQ:BLFS – Free Report ) by 11.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,351 shares of the medical equipment provider’s stock after buying an additional 3,967 shares during the period.
Alliancebernstein L.P. owned about 0.
08% of BioLife Solutions worth $970,000 as of its most recent SEC filing. Other institutional investors also recently bought and sold shares of the company. State Street Corp lifted its stake in BioLife Solutions by 7.
3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of BioLife Solutions by 2.
2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares in the last quarter. Barclays PLC grew its position in shares of BioLife Solutions by 20.
1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after buying an additional 10,803 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in BioLife Solutions during the 4th quarter worth $638,000.
Finally, Stifel Financial Corp lifted its position in BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after acquiring an additional 670 shares during the last quarter.
93.24% of the stock is owned by hedge funds and other institutional investors. Wall Street Analyst Weigh In Several research firms have recently weighed in on BLFS.
StockNews.com raised BioLife Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, April 8th. HC Wainwright lifted their target price on shares of BioLife Solutions from $27.
00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, Northland Securities increased their price target on shares of BioLife Solutions from $28.
00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock.
According to data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.17.
BioLife Solutions Stock Down 1.6 % BLFS stock opened at $21.91 on Friday.
BioLife Solutions, Inc. has a one year low of $15.72 and a one year high of $29.
55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.
78 and a current ratio of 2.78. The company has a fifty day moving average of $24.
62 and a 200-day moving average of $25.26. The stock has a market capitalization of $1.
04 billion, a PE ratio of -20.67 and a beta of 1.93.
BioLife Solutions ( NASDAQ:BLFS – Get Free Report ) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.
06) by $0.32. The company had revenue of $22.
71 million for the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.
61% and a negative net margin of 38.98%. During the same quarter in the previous year, the company earned ($0.
21) EPS. As a group, analysts expect that BioLife Solutions, Inc. will post -0.
3 EPS for the current year. Insider Activity In other BioLife Solutions news, insider Sarah Aebersold sold 1,091 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.
00, for a total value of $27,275.00. Following the sale, the insider now owns 58,816 shares of the company’s stock, valued at approximately $1,470,400.
This represents a 1.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website .
Also, CFO Troy Wichterman sold 4,151 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $103,775.
00. Following the transaction, the chief financial officer now directly owns 116,809 shares of the company’s stock, valued at $2,920,225. This trade represents a 3.
43 % decrease in their position. The disclosure for this sale can be found here . Insiders sold 72,127 shares of company stock worth $1,676,533 in the last 90 days.
2.20% of the stock is currently owned by corporate insiders. BioLife Solutions Profile ( Free Report ) BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. Featured Stories Five stocks we like better than BioLife Solutions What is the Nasdaq? Complete Overview with History J.B.
Hunt Transport Overcorrects Into a Buying Opportunity Stock Splits, Do They Really Impact Investors? AppLovin: Can Record Profits Overcome Market Skepticism? What Are Trending Stocks? Trending Stocks Explained MarketBeat Week in Review – 04/14 – 04/18 Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter ..
